Abstract
Background
Little is known about the epidemiology of biliary tract cancers over the last decade.
We investigated trends in incidence, treatment and prognosis of biliary tract cancers
according to anatomic site.
Methods
714 biliary tract cancers recorded between 2012 and 2019 in the French population-based
cancer registry of Burgundy were included. Trends in world age-standardized incidence
were depicted using Poisson regression.
Results
Intrahepatic cholangiocarcinoma accounted for 40% of biliary tract cancer. Half of
the patients were older than 75 years at diagnosis. Incidence of biliary tract cancer
did not vary over time, except a slight increase in intrahepatic cholangiocarcinoma
in men and a decrease in the ampulla in both sexes. Among non-metastatic patients,
the proportion who underwent R0 resection ranged from 15% for intrahepatic cholangiocarcinoma
to 58% for ampulla cancer (p < 0.001). Age, performance status and hospital type were
associated with resection. Among unresected patients, 45% received chemotherapy. Older
age, jaundice, increasing performance status and comorbidities index negatively affected
chemotherapy administration. Net survival was higher for ampulla than for other sites,
regardless of patient and treatment characteristics.
Conclusion
Biliary tract cancers present different patterns in incidence. The ampulla site should
be considered separately in clinical trials due to its better outcomes.
Graphical abstract
Graphical Abstract
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to HPBAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Biliary tract cancers.N Engl J Med. 1999; 341: 1368-1378https://doi.org/10.1056/NEJM199910283411807
- Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012.Cancer. 2020; 126: 2666-2678https://doi.org/10.1002/cncr.32803
- Gallbladder and extrahepatic bile duct cancers in the Americas: incidence and mortality patterns and trends.Int J Cancer. 2020; 147: 978-989https://doi.org/10.1002/ijc.32863
- Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise.Oncol. 2016; 21: 594-599https://doi.org/10.1634/theoncologist.2015-0446
- Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.Cancer. 2019; 125: 1489-1498https://doi.org/10.1002/cncr.31942
- Trends in the incidence and management of biliary tract cancer: a French population-based study.J Hepatol. 2011; 54: 306-310https://doi.org/10.1016/j.jhep.2010.06.039
- Biliary tract malignancies: a population-based study on incidence, prognosis and management of patients.Scand J Gastroenterol. 2016; 51: 1520-1525https://doi.org/10.1080/00365521.2016.1218538
- Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2016; 27: v28-v37https://doi.org/10.1093/annonc/mdw324
- Standards and guidelines for cancer registration in europe. Lyon.2003
- 3rd ed. International classification of diseases for Oncology. ICD-O-3, Lyon2000
- A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.J Chron Dis. 1987; 40: 373-383
- Toxicity and response criteria of the eastern cooperative Oncology group.Am J Clin Oncol. 1982; 5: 649-655
- Relative survival and the estimation of net survival: elements for further discussion.Stat Med. 1990; 9: 529-538
- Flexible parametric models for relative survival, with application in coronary heart disease.Stat Med. 2007; 26: 5486-5498
- Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification.Dig Dis Sci. 2014; 59: 3103-3110https://doi.org/10.1007/s10620-014-3276-2
- Current epidemiology of cholangiocarcinoma in Western countries.J Hepatol. 2022; 77: 1690-1698https://doi.org/10.1016/j.jhep.2022.07.022
- Trends in the mortality of biliary tract cancers based on their anatomical site in the United States from 2009 to 2018.Am J Gastroenterol. 2021; 116: 1053-1062https://doi.org/10.14309/ajg.0000000000001151
- Age trends in biliary tract cancer incidence by anatomical subtype: a Swedish cohort study.Eur J Cancer. 2022; 175: 291-298https://doi.org/10.1016/j.ejca.2022.08.032
- Long-term incidence in hepatocellular carcinoma and intrahepatic bile duct cancer in Denmark, Finland, Norway and Sweden, role of Thorotrast?.Int J Cancer. 2022; 151: 510-517https://doi.org/10.1002/ijc.34031
- Long-term incidence and survival trends in cancer of the gallbladder and extrahepatic bile ducts in Denmark, Finland, Norway and Sweden with etiological implications related to Thorotrast.Int J Cancer. 2022; 151: 200-208https://doi.org/10.1002/ijc.33980
- Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study.Sci Rep. 2022; 12: 10206https://doi.org/10.1038/s41598-022-13605-3
- Changing epidemiological trends of hepatobiliary carcinomas in Austria 2010-2018.Cancers. 2022; 14https://doi.org/10.3390/cancers14133093
- The epidemiological trends of biliary tract cancers in the United States of America.BMC Gastroenterol. 2022; 22: 546https://doi.org/10.1186/s12876-022-02637-8
- Temporal changes in cholangiocarcinoma incidence and mortality in the United States from 2001 to 2017.Oncol. 2022; 27: 874-883https://doi.org/10.1093/oncolo/oyac150
- Epidemiologic patterns of biliary tract cancer in the United States: 2001-2015.BMC Cancer. 2022; 22: 1178https://doi.org/10.1186/s12885-022-10286-z
- Biliary tract cancer.Lancet. 2021; 397: 428-444https://doi.org/10.1016/S0140-6736(21)00153-7
- Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma.Cancer. 2016; 122: 1349-1369https://doi.org/10.1002/cncr.29692
- Vascular resection for intrahepatic cholangiocarcinoma: current considerations.J Clin Med. 2021; : 10https://doi.org/10.3390/jcm10173829
- Surgical management of intrahepatic cholangiocarcinoma--a population-based study.Ann Surg Oncol. 2008; 15: 600-608https://doi.org/10.1245/s10434-007-9627-x
- Disparities in the diagnosis and treatment of bile duct cancer in people with disabilities: a national cohort study in South Korea.Int J Environ Res Publ Health. 2022; 19https://doi.org/10.3390/ijerph192416625
- Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study.Acta Oncol. 2019; 58: 1048-1055https://doi.org/10.1080/0284186X.2019.1590634
- Nationwide treatment and outcomes of perihilar cholangiocarcinoma.Liver Int. 2021; 41: 1945-1953https://doi.org/10.1111/liv.14856
- Geographic disparities in referral rates and oncologic outcomes of intrahepatic cholangiocarcinoma: a population-based study.Ann Surg Oncol. 2021; 28: 8152-8159https://doi.org/10.1245/s10434-021-10650-6
- Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.J Hepatol. 2022; 76: 1109-1121https://doi.org/10.1016/j.jhep.2021.12.010
- Ampulla of Vater carcinoma: molecular landscape and clinical implications.World J Gastrointest Oncol. 2018; 10: 370-380https://doi.org/10.4251/wjgo.v10.i11.370
- Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.J Hepatol. 2020; 73: 1109-1117https://doi.org/10.1016/j.jhep.2020.05.014
- Advances in the systemic treatment of therapeutic approaches in biliary tract cancer.ESMO Open. 2022; 7: 100503https://doi.org/10.1016/j.esmoop.2022.100503
- Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Ann Oncol. 2022; https://doi.org/10.1016/j.annonc.2022.10.506
Article info
Publication history
Published online: February 27, 2023
Accepted:
February 23,
2023
Received:
December 1,
2022
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
